Clobetasol propionate
- Generic Name
- Clobetasol propionate
- Brand Names
- Clobex, Clodan, Dermovate, Impeklo, Impoyz, Olux, Temovate, Tovet
- Drug Type
- Small Molecule
- Chemical Formula
- C25H32ClFO5
- CAS Number
- 25122-46-7
- Unique Ingredient Identifier
- 779619577M
- Background
Clobetasol propionate is a prednisolone derivative with higher specificity for glucocorticoid receptors than mineralocorticoid receptors. It has demonstrated superior activity compared to fluocinonide and was first described in the literature in 1974.
Clobetasol Propionate was granted FDA approval on 27 December 1985.
- Indication
Clobetasol propionate is indicated to treat moderate to severe plaque psoriasis as well as inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
- Associated Conditions
- Alopecia, Severe Plaque psoriasis, Corticosteroid responsive, Inflammatory Dermatosis, Corticosteroid responsive, pruritic Dermatosis, Moderate Plaque psoriasis, Moderate Scalp Psoriasis, Severe Scalp Psoriasis
A Comparison of Photodynamic Therapy and Topical Clobetasol in Treatment of Oral Lichen Planus: a Split-Mouth Randomised Controlled Study
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Wroclaw Medical University
- Target Recruit Count
- 29
- Registration Number
- NCT06752343
- Locations
- 🇵🇱
Wroclaw Medical Univeristy, Departament of Periodontology, Wroclaw, Poland
Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Centre Hospitalier Universitaire de Nice
- Target Recruit Count
- 40
- Registration Number
- NCT06742333
- Locations
- 🇫🇷
CHU de Nice - Hôpital de l'Archet, Nice, Alpes-Maritimes, France
🇫🇷Hôpital Edouard Herriot, Lyon, France
🇫🇷Hôpital Saint-Joseph, Marseille, France
Topical 1% Methotrexate Gel Versus Clobetasol Propionate in Patients With Psoriasis
- Conditions
- Pilot StudyPsoriasis
- Interventions
- Drug: topical 1% methotrexate gel
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Dr. Jose N. Rodriguez Memorial Hospital and Sanitarium
- Target Recruit Count
- 2
- Registration Number
- NCT06555497
- Locations
- 🇵🇭
Dr. Jose N. Rodriguez Memorial Hospital and Sanitarium, Caloocan, Metro Manila, Philippines
Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: ShA9 Topical GelDrug: Placebo (Vehicle) Topical Gel
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2025-05-11
- Target Recruit Count
- 86
- Registration Number
- NCT06504160
- Locations
- 🇺🇸
University of California, San Diego: Dermatology Clinical Trials Unit, San Diego, California, United States
🇺🇸National Jewish Health: Division of Pediatric Allergy and Clinical Immunology, Denver, Colorado, United States
🇺🇸Northwestern University Feinberg School of Medicine: Department of Dermatology, Chicago, Illinois, United States
Silver Nitrate Versus Topical Steroid For Umbilical Granuloma
- Conditions
- Umbilical Granuloma
- Interventions
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Children Hospital and Institute of Child Health, Lahore
- Target Recruit Count
- 354
- Registration Number
- NCT06363539
- Locations
- 🇵🇰
Children Hospital, Lahore, Punjab, Pakistan
Impact of Topical Clobetasol on Gingival Crevicular Fluid miRNAs in Subjects Affected by Oral Lichen Planus
- Conditions
- Oral Lichen Planus
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- University of Catania
- Target Recruit Count
- 64
- Registration Number
- NCT05818618
- Locations
- 🇮🇹
AOU Policlinico G. Rodolico, Catania, Italy
Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population
- Conditions
- Cataracts Infantile
- Interventions
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- Salvat
- Target Recruit Count
- 60
- Registration Number
- NCT05724446
- Locations
- 🇪🇸
Hospìtal Sant Joan de Deu, Barcelone, Spain
Phase II Study Evaluating the Clinical Efficacy and Safety of GN-037 in Plaque Psoriasis
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2023-01-31
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- GEN İlaç ve Sağlık Ürünleri A.Ş.
- Target Recruit Count
- 190
- Registration Number
- NCT05706870
- Locations
- 🇹🇷
Uludag University Faculty of Medicine, Bursa, Turkey
🇹🇷Ataturk University Research Hospital, Erzurum, Turkey
🇹🇷Pamukkale University Faculty of Medicine, Denizli, Turkey
Plasma Rich in Growth Factors (PRGF) for the Treatment of Lichen Sclerosus Atrophicus of the Vulva
- Conditions
- Lichen Sclerosus of Vulva
- Interventions
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Fundación Eduardo Anitua
- Target Recruit Count
- 30
- Registration Number
- NCT05364515
Laser Vs Clobetasol for Lichen Sclerosus
- Conditions
- Lichen Sclerosus
- Interventions
- Device: Non-ablative CO2 Laser
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Ruhr University of Bochum
- Target Recruit Count
- 198
- Registration Number
- NCT05010421
- Locations
- 🇩🇪
Marien Hospital Herne, Herne, NRW, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.